3rd ESTRO Forum 2015 studies. Possible future options may include the addition WBRT with doses per fraction of <3 Gy and sparing of the hippocampus to reduce the risk of neurocognitive decline. Patients with a limited number of brain metastases who are not candidates for SRS, FSRT and neurosurgery or do not wish such a treatment may receive WBRT plus a simultaneous integrated boost (SIB) to the metastatic lesions.
SP-0003
Update on current consensus agreement on lung palliative radiotherapy A. Bezjak 1 1 Princess Margaret Cancer Centre, Dept of Radiation Oncology, Toronto, Canada
Background: Despite many advances in management of nonsmall cell lung cancer (NSCLC), there is still a significant role for palliative radiotherapy (RT) -both external beam , and less often, brachytherapy, for symptomatic management of patients with symptoms due to their thoracic disease, including cough, hemoptysis, dyspnea and chest pain. Many fractionation schedules have been found to be effective, and practices differ across centers and countries (1) . The Third International Consensus Conference Workshop was held at ASTRO meeting in 2010 (2),followed by the publication of the ASTRO evidence-based clinical practice guideline for palliative thoracic RT in lung cancer (3) that favoured shorter RT schedules as providing good symptomatic relief with fewer side-effects, and highlighted the lack of evidence on how to integrate concurrent chemotherapy with palliative RT. Methods: Given the importance of remaining current with evidence in the management of patients with metastatic disease, the Fourth International Consensus Conference Workshop on Palliative Radiotherapy was convened to coincide with the 2015 ESTRO Meeting. Attendees are planning to discuss research updates that have been published since the 2010 International Conference, and discuss areas of controversy and questions that require further evidence. Results: The Cochrane review of palliative RT for patients with thoracic symptoms from NSCLC has been recently updated and published (4). It includes 14 randomized controlled trials (RCTs) and more than 3500 patients. All trials confirmed symptom palliation from the variety of RT regimens, and relatively mild toxicity with shorter RT schedules. The evidence that higher dose palliative RT prolongs survival is not strong, limited in part by the heterogeneity among studies. A more recent RCT (5, 6) not included in the Cochrane review compared chemotherapy to chemotherapy with concurrent moderate dose RT (42Gy/15 fr) and demonstrated improved survival but at the expense of toxicity, although quality of life was maintained. Other studies and evidence will be discussed at the workshop. Conclusion: The results of the 2015 ESTRO International Consensus Conference Workshop will identify current evidence and best practices as well as current research and clinical questions, and will set the stage for the Fifth Conference to be held in 2020. 
SP-0004 Radiotherapy for liver metastases M. Hoyer 1 1 Aarhus University Hospital, Department of Oncology, Risskov, Denmark
Radiation therapy for metastases of the liver includes number of techniques ranging from whole liver radiation therapy (WLRT), selective internal radiation therapy (SIRT), brachytherapy, conformal fractionated radiotherapy to stereotactic techniques (SBRT). WLRT is considered palliative and non-ablative whereas SBRT with high doses is ablative and a potentially curative therapy. Five years back we had only few publications on the outcome after radiotherapy for liver metastases. Due to the relatively low quality of the primary literature, it was decided not to write a guideline for SBRT of metastases. Instead, the ASTRO, CARO, ESTRO and TROG working group wrote a review of published evidence on radiotherapy technologies and clinical outcome in therapy of liver metastases 1 . The review was followed by an international survey to describe the utilization of radiation therapy for liver metastases 2 . The survey revealed an increasing utilization of radiation therapy in general and SBRT in particular for therapy of liver metastases. A number of retrospective and prospective studies have been published since and there are initiatives to unite forces and contribute to large multi-institutional databases. We are still awaiting a successful prospective trial within this field. The liver session will focus on perspectives within the field for the next five years.
